Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2009 |
| gptkbp:ATCCode |
L01XC10
|
| gptkbp:brand |
gptkb:Kesimpta
Arzerra |
| gptkbp:CASNumber |
679818-59-8
|
| gptkbp:developedBy |
gptkb:Novartis
gptkb:Genmab |
| gptkbp:drugClass |
immunosuppressant
|
| https://www.w3.org/2000/01/rdf-schema#label |
ofatumumab
|
| gptkbp:indication |
relapsing forms of multiple sclerosis
refractory chronic lymphocytic leukemia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:CD20_antigen
|
| gptkbp:mechanismOfAction |
B cell depletion
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
DB06650
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
fever
headache injection site reaction upper respiratory tract infection |
| gptkbp:target |
gptkb:CD20
|
| gptkbp:UNII |
JX8W1O6CMO
|
| gptkbp:usedFor |
multiple sclerosis
chronic lymphocytic leukemia |
| gptkbp:bfsParent |
gptkb:Kesimpta
|
| gptkbp:bfsLayer |
6
|